Neurogene Inc.
NASDAQ:NGNEBiotechnology
Healthcare
$23.14 +2.47%
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
52W Low $14.65High $37.27
Volume 0.25M
Average 0.16M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$103.21M
FY 2025 · Annual
Net Income
-$90.35M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 925K | 0 |
| Cost of Revenue | 42.26M | 3.2M | 3.26M | 3.25M | 3.19M |
| Gross Profit | (42.26M) | (3.2M) | (3.26M) | (2.32M) | (3.19M) |
| Gross Margin | — | — | — | -251.0% | — |
| Research & Development | 42.26M | 47.51M | 44.39M | 60.92M | 75.01M |
| Selling, General & Admin | 8.27M | 9.01M | 11.19M | 22.61M | 25.13M |
| Operating Expenses | 8.27M | 53.32M | 52.32M | 80.28M | 100.02M |
| Depreciation & Amortization | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
| EBITDA | (49.57M) | (51.99M) | (33.01M) | (71.89M) | (87.25M) |
| EBITDA Margin | — | — | — | -7771.4% | — |
| Operating Income | (50.53M) | (56.52M) | (55.58M) | (82.61M) | (103.21M) |
| Operating Margin | — | — | — | -8930.3% | — |
| Interest Income | 19K | 1.34M | 2.95M | 8.47M | 11.55M |
| Interest Expense | 0 | 2K | 12K | 12K | 5K |
| Other Income / Expenses | 17K | 1.33M | 19.27M | 7.46M | 12.86M |
| Income Before Tax | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Pre-Tax Margin | — | — | — | -8123.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Net Margin | — | — | — | -8123.7% | — |
| EPS (Basic) | (0.92) | (4.30) | (2.83) | (4.28) | (4.24) |
| EPS (Diluted) | (0.92) | (4.30) | (2.83) | (4.28) | (4.24) |
| 55.04M | 12.82M | 12.82M | 17.57M | 21.17M | |
| 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
NGNE Earnings Waterfall · TTM
NASDAQ:NGNE · Revenue to Net Income
Key Ratios
EPS$-5.03
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$98.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-5.03, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 | |
| SC 13G | SC 13G filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
How much revenue does NGNE generate?
Neurogene Inc. (NGNE) reported $0.00 of revenue in fiscal 2025.
Is NGNE profitable?
Neurogene Inc. (NGNE) reported -$90.35M of net income.
Continue the stock analysis
Jump to another research area for this company.